A5047940829- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Testicular diseases and treatments
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Sarcoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Urologic and reproductive health conditions
- Prostate Cancer Diagnosis and Treatment
- Enhanced Recovery After Surgery
- Prostate Cancer Treatment and Research
- Urinary Tract Infections Management
- Ureteral procedures and complications
- Sexual Differentiation and Disorders
- Neuroblastoma Research and Treatments
- Multiple and Secondary Primary Cancers
- Urinary Bladder and Prostate Research
- Pelvic floor disorders treatments
- Fibroblast Growth Factor Research
- Renal and related cancers
- Colorectal Cancer Surgical Treatments
- Infectious Disease Case Reports and Treatments
- Colorectal Cancer Screening and Detection
- Cardiac, Anesthesia and Surgical Outcomes
University of Southern California
2016-2025
USC Norris Comprehensive Cancer Center
2016-2025
Keck Hospital of USC
2012-2024
Southern California University for Professional Studies
2011-2024
City Of Hope National Medical Center
2024
Stanford University
2014-2024
The University of Texas Southwestern Medical Center
2024
City of Hope
2024
The University of Texas Health Science Center at San Antonio
2024
University of Alberta
2024
To evaluate the performance of active surveillance as a management strategy in broad populations and to inform development schedules by individual patient data regarding timing type relapse.Retrospective study including from 2,483 clinical stage I (CSI) patients, 1,139 CSI nonseminoma 1,344 seminoma managed with surveillance, majority treated between 1998 2010. Clinical outcomes relapse death, time distribution, extent method detection observed on were recorded.Relapse occurred 221 (19%)...
No AccessJournal of UrologyAdult Urology1 Jul 2014Enhanced Recovery Protocol after Radical Cystectomy for Bladder Cancer Siamak Daneshmand, Hamed Ahmadi, Anne K. Schuckman, Anirban P. Mitra, Jie Cai, Gus Miranda, and Hooman Djaladat DaneshmandSiamak Daneshmand Financial interest and/or other relationship with Cubist Endo. More articles by this author , AhmadiHamed Ahmadi SchuckmanAnne Schuckman Photocure. MitraAnirban Mitra CaiJie Cai MirandaGus Miranda DjaladatHooman View All Author...
No AccessJournal of UrologyAdult Urology1 Oct 2011Super Extended Versus Pelvic Lymph Node Dissection in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Comparative Study Pascal Zehnder, Urs E. Studer, Eila C. Skinner, Ryan P. Dorin, Jie Cai, Beat Roth, Gus Miranda, Frédéric Birkhäuser, John Stein, Fiona Burkhard, Sia Daneshmand, George N. Thalmann, Inderbir S. Gill, and Donald G. Skinner ZehnderPascal Zehnder University Southern California Institute Urology, Catherine Joseph...
Testis cancer is the most common solid malignancy in young males. The purpose of this guideline to provide a useful reference on effective evidence-based treatment early stage testicular cancer.The systematic review utilized inform was conducted by methodology team at Johns Hopkins University Evidence-based Practice Center. searched using PubMed®, Embase®, and Cochrane Central Register Controlled Trials (CENTRAL) from January 1980 through August 2018. evidence also reviewed relevant reviews...
The long-term toxicities of chemotherapy and radiotherapy can represent a significant burden to testicular cancer survivors. Retroperitoneal lymph node dissection (RPLND) is an established treatment for germ cell tumors with minimal late morbidity although little data exist on its efficacy in early metastatic seminoma. Surgery seminoma prospective phase II single-arm, multi-institutional trial RPLND as first-line clinically low-volume retroperitoneal lymphadenopathy.
Abstract Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it life-altering. We initiated phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients achieving complete response (cCR) could proceed without cystectomy. The co-primary objectives were to assess the cCR rate and positive predictive value composite outcome: 2-year metastasis-free survival forgoing immediate...
We determined the prognostic factors that affect recurrence and survival in patients with lymph node positive prostate cancer.Between 1972 1999, 1,936 underwent radical retropubic prostatectomy pelvic dissection for clinically organ confined cancer. A total of 235 (12.1%) were found to have disease metastatic nodes (stage D1). Of 69% received no adjuvant treatment. reviewed tumor stage (TNM), Gleason score, number percent involved (lymph density), preoperative specific antigen when available...
No AccessJournal of UrologyAdult Urology1 Jan 2014Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy Stephen H. Culp, Rian J. Dickstein, Barton Grossman, Shanna M. Pretzsch, Sima Porten, Siamak Daneshmand, Jie Cai, Susan Groshen, Arlene Siefker-Radtke, Randall E. Millikan, Bogdan Czerniak, Neema Navai, Matthew F. Wszolek, Ashish Kamat, and Colin P.N. Dinney CulpStephen Culp Department Urology, University Virginia, Charlottesville, California , DicksteinRian...
The management of patients with a radiographic complete response after chemotherapy remains controversial. current study assesses the outcome for modern, unselected patient population disseminated testicular cancer particular emphasis on those achieving remission to combination chemotherapy.All nonseminoma seen between 1999 and 2007 at British Columbia Cancer Agency (BCCA) as well through Oregon Testis Program were retrospectively reviewed. A total 276 treated identified. (CR) was defined...